Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India.
Sanofi India Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹8,154.60|
|52 Week High||₹7,427.75|
|52 Week Low||₹9,300.00|
|1 Month Change||1.51%|
|3 Month Change||2.40%|
|1 Year Change||-5.99%|
|3 Year Change||37.76%|
|5 Year Change||88.65%|
|Change since IPO||2,229.89%|
Recent News & Updates
|500674||IN Pharmaceuticals||IN Market|
Return vs Industry: 500674 underperformed the Indian Pharmaceuticals industry which returned 23.5% over the past year.
Return vs Market: 500674 underperformed the Indian Market which returned 68.3% over the past year.
Stable Share Price: 500674 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 500674's weekly volatility (4%) has been stable over the past year.
About the Company
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, allergy and vitamins, and minerals and supplements. The company exports its products to approximately 50 countries, including Germany, the Czech Republic, Australia, the United Kingdom, and Russia.
Sanofi India Fundamentals Summary
|500674 fundamental statistics|
Is 500674 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|500674 income statement (TTM)|
|Cost of Revenue||₹12.89b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 26, 2021
|Earnings per share (EPS)||251.89|
|Net Profit Margin||19.86%|
How did 500674 perform over the long term?See historical performance and comparison
1.5%Current Dividend Yield
Is Sanofi India undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 500674 (₹8154.6) is trading below our estimate of fair value (₹12518.1)
Significantly Below Fair Value: 500674 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 500674 is poor value based on its PE Ratio (32.4x) compared to the Indian Pharmaceuticals industry average (26x).
PE vs Market: 500674 is poor value based on its PE Ratio (32.4x) compared to the Indian market (22.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500674's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500674 is overvalued based on its PB Ratio (11.7x) compared to the IN Pharmaceuticals industry average (3.2x).
How is Sanofi India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sanofi India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Sanofi India performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500674 has high quality earnings.
Growing Profit Margin: 500674's current net profit margins (19.9%) are higher than last year (14.3%).
Past Earnings Growth Analysis
Earnings Trend: 500674's earnings have grown by 13.4% per year over the past 5 years.
Accelerating Growth: 500674's earnings growth over the past year (30.2%) exceeds its 5-year average (13.4% per year).
Earnings vs Industry: 500674 earnings growth over the past year (30.2%) underperformed the Pharmaceuticals industry 35.8%.
Return on Equity
High ROE: 500674's Return on Equity (36.1%) is considered high.
How is Sanofi India's financial position?
Financial Position Analysis
Short Term Liabilities: 500674's short term assets (₹14.6B) exceed its short term liabilities (₹7.8B).
Long Term Liabilities: 500674's short term assets (₹14.6B) exceed its long term liabilities (₹1.1B).
Debt to Equity History and Analysis
Debt Level: 500674 is debt free.
Reducing Debt: 500674 had no debt 5 years ago.
Debt Coverage: 500674 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 500674 has no debt, therefore coverage of interest payments is not a concern.
What is Sanofi India current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 500674's dividend (1.53%) is higher than the bottom 25% of dividend payers in the Indian market (0.33%).
High Dividend: 500674's dividend (1.53%) is in the top 25% of dividend payers in the Indian market (1.35%)
Stability and Growth of Payments
Stable Dividend: 500674's dividend payments have been volatile in the past 10 years.
Growing Dividend: 500674's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (49.6%), 500674's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rajaram Narayanan (53 yo)
Mr. Rajaram Narayanan serves as Managing Director and Whole Time Director at Sanofi India Ltd. since January 01, 2018 and since October 21, 2015 respectively. Mr. Narayanan serves as Director of Sanofi-Syn...
CEO Compensation Analysis
Compensation vs Market: Rajaram's total compensation ($USD546.38K) is about average for companies of similar size in the Indian market ($USD579.67K).
Compensation vs Earnings: Rajaram's compensation has been consistent with company performance over the past year.
Experienced Management: 500674's management team is seasoned and experienced (7.8 years average tenure).
Experienced Board: 500674's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sanofi India Limited's employee growth, exchange listings and data sources
- Name: Sanofi India Limited
- Ticker: 500674
- Exchange: BSE
- Founded: 1956
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹187.800b
- Shares outstanding: 23.03m
- Website: https://www.sanofiindialtd.com
Number of Employees
- Sanofi India Limited
- Sanofi House
- CTS No. 117-B, L&T Business Park
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 12:01|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.